JP2021515559A5 - - Google Patents

Info

Publication number
JP2021515559A5
JP2021515559A5 JP2020546857A JP2020546857A JP2021515559A5 JP 2021515559 A5 JP2021515559 A5 JP 2021515559A5 JP 2020546857 A JP2020546857 A JP 2020546857A JP 2020546857 A JP2020546857 A JP 2020546857A JP 2021515559 A5 JP2021515559 A5 JP 2021515559A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
isolated antibody
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515559A (ja
JP7319992B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021313 external-priority patent/WO2019173692A2/en
Publication of JP2021515559A publication Critical patent/JP2021515559A/ja
Publication of JP2021515559A5 publication Critical patent/JP2021515559A5/ja
Priority to JP2023119139A priority Critical patent/JP2023129543A/ja
Application granted granted Critical
Publication of JP7319992B2 publication Critical patent/JP7319992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546857A 2018-03-09 2019-03-08 抗cd73抗体およびそれらの使用方法 Active JP7319992B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023119139A JP2023129543A (ja) 2018-03-09 2023-07-21 抗cd73抗体およびそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862640850P 2018-03-09 2018-03-09
US62/640,850 2018-03-09
PCT/US2019/021313 WO2019173692A2 (en) 2018-03-09 2019-03-08 Anti-cd73 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023119139A Division JP2023129543A (ja) 2018-03-09 2023-07-21 抗cd73抗体およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2021515559A JP2021515559A (ja) 2021-06-24
JP2021515559A5 true JP2021515559A5 (cg-RX-API-DMAC7.html) 2022-03-14
JP7319992B2 JP7319992B2 (ja) 2023-08-02

Family

ID=65904555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546857A Active JP7319992B2 (ja) 2018-03-09 2019-03-08 抗cd73抗体およびそれらの使用方法
JP2023119139A Withdrawn JP2023129543A (ja) 2018-03-09 2023-07-21 抗cd73抗体およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023119139A Withdrawn JP2023129543A (ja) 2018-03-09 2023-07-21 抗cd73抗体およびそれらの使用方法

Country Status (19)

Country Link
US (2) US11692042B2 (cg-RX-API-DMAC7.html)
EP (1) EP3762421A2 (cg-RX-API-DMAC7.html)
JP (2) JP7319992B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200130403A (cg-RX-API-DMAC7.html)
CN (2) CN119431579A (cg-RX-API-DMAC7.html)
AR (1) AR114275A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019231791B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017382A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093468A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002314A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200392A (cg-RX-API-DMAC7.html)
EA (1) EA202091710A1 (cg-RX-API-DMAC7.html)
IL (1) IL276731A (cg-RX-API-DMAC7.html)
MX (1) MX2020009394A (cg-RX-API-DMAC7.html)
PE (1) PE20210628A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551317A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007927WA (cg-RX-API-DMAC7.html)
TW (1) TWI823906B (cg-RX-API-DMAC7.html)
WO (1) WO2019173692A2 (cg-RX-API-DMAC7.html)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN119431579A (zh) 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
JP7148037B2 (ja) 2018-12-03 2022-10-05 イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド Pd-l1とvegfを標的化する組換えタンパク質
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
EP4025605A1 (en) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
EP4058150A2 (en) * 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗-cd70抗體治療癌症之方法
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CR20220317A (es) * 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN115379848A (zh) * 2020-04-01 2022-11-22 加利福尼亚大学董事会 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CN115734972A (zh) * 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
CN113817770B (zh) * 2020-08-12 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Cd73基因人源化的非人动物的构建方法及应用
KR20230050378A (ko) * 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
WO2022037531A1 (zh) * 2020-08-17 2022-02-24 中山康方生物医药有限公司 抗cd73的抗体及其用途
WO2022060477A1 (en) * 2020-09-16 2022-03-24 Board Of Regents, The University Of Texas System Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
IL301376A (en) * 2020-09-23 2023-05-01 Medimmune Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4251650A4 (en) * 2020-11-27 2024-10-23 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta
CN116940592A (zh) * 2020-12-15 2023-10-24 比卡拉治疗股份有限公司 用于治疗癌症的组合疗法
CN112538088B (zh) * 2020-12-22 2022-02-22 中山大学 一类抗前列腺癌的瑞香烷型二萜及其制备方法
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
JP2024508222A (ja) * 2021-01-29 2024-02-26 アムジエン・インコーポレーテツド 抗Mcl1抗体を投与することによる癌を監視するための材料及び方法
EP4299589A4 (en) * 2021-02-24 2025-06-11 Novoprotein Scientififc Inc. HUMAN ANTI-CD73 ANTIBODY AND ITS USE
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
TW202308629A (zh) 2021-04-28 2023-03-01 法商Enyo製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US20240261333A1 (en) * 2021-06-03 2024-08-08 The Broad Institute, Inc. Novel targets for enhancing anti-tumor immunity
JP7900421B2 (ja) * 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023280880A1 (en) * 2021-07-05 2023-01-12 Trion Research Gmbh Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
WO2023154829A2 (en) * 2022-02-09 2023-08-17 Absci Corporation Unlocking de novo antibody design with generative artificial intelligence
WO2023164625A2 (en) * 2022-02-25 2023-08-31 Georgia Tech Research Corporation Modified plant virus system for delivery of nucleic acids into mammalian cells
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4321537A4 (en) * 2022-06-22 2025-04-23 Akeso Biopharma, Inc. Pharmaceutical composition and use thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024010842A1 (en) * 2022-07-07 2024-01-11 The Board Of Trustees Of The Leland Stanford Junior University Targeting cells with a combination of cxcr2 inhibition and cd47 blockade
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN118812710A (zh) * 2023-04-17 2024-10-22 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024267583A1 (en) * 2023-05-07 2025-11-13 Bioatla, Inc. Protein therapeutics for treatment of senescent cells
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
JP2026526882A (ja) * 2023-07-25 2026-08-10 イミュニティーバイオ、インコーポレイテッド Lair-2及びtnt-トラップ組成物及び方法
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
CN122161845A (zh) * 2023-10-04 2026-06-05 艾吉纳斯公司 TGFβRII胞外区变体及其用途
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN117805390A (zh) * 2023-12-19 2024-04-02 哈尔滨医科大学 用于评估患者pci术后心肌缺血再灌注损伤和死亡风险的乳酰化修饰蛋白标志物及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118420709B (zh) * 2024-04-29 2025-02-14 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN119431583B (zh) * 2024-12-19 2025-09-30 重庆国际免疫创新中心有限公司 靶向cd155的抗体或抗原结合片段及其应用
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors
CN120965881B (zh) * 2025-08-19 2026-07-17 合肥综合性国家科学中心大健康研究院 抗猪b细胞表面cd27的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2136016B (en) 1983-03-07 1987-01-07 Sheena Margaret Johnson Monoclonal factor having 5'-nucleotidase inhibitory activity
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CN1257545A (zh) 1997-04-18 2000-06-21 拜奥根有限公司 Ⅱ型TGF-β受体/免疫球蛋白恒定区融合蛋白
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2001080884A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
NZ555286A (en) 2004-12-17 2010-04-30 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
EP1883424A2 (en) 2005-05-18 2008-02-06 Biogen Idec Inc. Methods for treating fibrotic conditions
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
WO2008113185A1 (en) 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
JP2010529859A (ja) 2007-06-15 2010-09-02 ジェンザイム、コーポレーション TGF−βII型受容体の2つのTGF−β結合ドメインを含有する融合タンパク質
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル, エルエルシー TGF−βアンタゴニスト多重標的結合性分子
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
WO2013149094A1 (en) 2012-03-28 2013-10-03 The Board Of Regents Of The University Of Texas System TGFβ TYPE II-TYPE III RECEPTOR FUSIONS
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
US10206941B2 (en) 2013-07-09 2019-02-19 President And Fellows Of Harvard College Venule endothelial cell genes and uses thereof
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
EP3259288B1 (en) * 2015-02-20 2026-07-22 Innate Pharma Cd73 blockade
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
EP3436829A1 (en) 2016-03-30 2019-02-06 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
CN109414500B (zh) 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
EP3481869A4 (en) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
CA3046432A1 (en) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anti-human cd73 antibody
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN119431579A (zh) * 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP7822325B2 (ja) 抗cd73抗体およびその使用
ES2387809T3 (es) Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
TWI831778B (zh) 抗ox40的全人抗體及其製備方法和用途
JP2024527606A5 (cg-RX-API-DMAC7.html)
JP2020529863A5 (cg-RX-API-DMAC7.html)
JP2021518103A5 (cg-RX-API-DMAC7.html)
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2021531764A5 (cg-RX-API-DMAC7.html)
JPWO2021177438A5 (cg-RX-API-DMAC7.html)
TW202537975A (zh) 抗體-藥物結合物之製造方法
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2018509175A (ja) 二重特異性四価抗体並びにその製作及び使用方法
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2020527332A5 (cg-RX-API-DMAC7.html)
TW202245846A (zh) 含抗her2抗體-藥物結合物之治療劑
US20170291961A1 (en) Multivalent fragments of antibody 3e10 and methods of use thereof
CN113214400B (zh) 一种双特异性抗pd-l1/vegf抗体及其用途
JP2018516966A5 (cg-RX-API-DMAC7.html)
JP7692422B2 (ja) 二重特異性抗pd-l1/vegf抗体及びその使用
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
JP2022550364A (ja) 新規抗pd-l1/抗lag-3二重特異性抗体およびその使用
JP2022551380A (ja) Frizzled受容体抗体およびその使用
CN119095624A (zh) 抗体-药物缀合物与ezh1和/或ezh2抑制剂的组合
TW202302630A (zh) 新穎多特異性抗體